Compare SKYH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | ENTA |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.1M | 377.5M |
| IPO Year | 2020 | 2012 |
| Metric | SKYH | ENTA |
|---|---|---|
| Price | $9.47 | $12.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $16.19 | ★ $21.83 |
| AVG Volume (30 Days) | 118.5K | ★ 210.9K |
| Earning Date | 11-11-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.11 | 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | $27,540,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $47.34 | N/A |
| Revenue Next Year | $67.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.57 | 16.48 |
| 52 Week Low | $8.22 | $10.12 |
| 52 Week High | $11.70 | $17.15 |
| Indicator | SKYH | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 30.91 | 53.45 |
| Support Level | $9.07 | $12.88 |
| Resistance Level | $9.60 | $14.03 |
| Average True Range (ATR) | 0.22 | 0.51 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 0.00 | 83.62 |
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.